Disease-Based Prognostication: Neuro-Oncology

Kristin A. Waite; Gino Cioffi; Mark G. Malkin; Jill S. Barnholtz-Sloan

doi:10.1055/s-0043-1775751

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2023; 43(05): 768-775
DOI: 10.1055/s-0043-1775751

Review Article

Disease-Based Prognostication: Neuro-Oncology

Authors

Kristin A. Waite^*

¹Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, National Cancer Institute, Bethesda, Maryland

²Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois
Gino Cioffi^*

¹Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, National Cancer Institute, Bethesda, Maryland

²Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois
Mark G. Malkin^**

³Cleveland Clinic, Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland, Ohio
Jill S. Barnholtz-Sloan^**

¹Division of Cancer Epidemiology and Genetics, Trans-Divisional Research Program, National Cancer Institute, Bethesda, Maryland

²Central Brain Tumor Registry of the United States (CBTRUS), Hinsdale, Illinois

⁴Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland

Abstract

Primary malignant and non-malignant brain and other central nervous system (CNS) tumors, while relatively rare, are a disproportionate source of morbidity and mortality. Here we provide a brief overview of approaches to modeling important clinical outcomes, such as overall survival, that are critical for clinical care. Because there are a large number of histologically distinct types of primary malignant and non-malignant brain and other CNS tumors, this chapter will provide an overview of prognostication considerations on the most common primary non-malignant brain tumor, meningioma, and the most common primary malignant brain tumor, glioblastoma. In addition, information on nomograms and how they can be used as individualized prognostication tools by clinicians to counsel patients and their families regarding treatment, follow-up, and prognosis is described. The current state of nomograms for meningiomas and glioblastomas are also provided.

Keywords

meningioma - glioblastoma - clinical outcomes - nomogram - biomarkers

Volltext

Referenzen

References
1 Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro-oncol 2021; 23 (12, suppl 2): iii1-iii105
2 Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 2010; 143 (03) 331-336
3 In J, Lee DK. Survival analysis: part II - applied clinical data analysis. Korean J Anesthesiol 2019; 72 (05) 441-457
4 Islim AI, Mohan M, Moon RDC. et al. Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. J Neurooncol 2019; 142 (02) 211-221
5 Larjavaara S, Haapasalo H, Sankila R, Helén P, Auvinen A. Is the incidence of meningiomas underestimated? A regional survey. Br J Cancer 2008; 99 (01) 182-184
6 Li XR, Kruchko C, Wu XC. et al. Are benign and borderline brain tumors underreported?. J Registry Manag 2016; 43 (04) 187-194
7 Louis DN, Perry A, Wesseling P. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncol 2021; 23 (08) 1231-1251
8 Zamanipoor Najafabadi AH, van der Meer PB, Boele FW. et al; Dutch Meningioma Consortium. Determinants and predictors for the long-term disease burden of intracranial meningioma patients. J Neurooncol 2021; 151 (02) 201-210
9 Gondar R, Patet G, Schaller K, Meling TR. Meningiomas and cognitive impairment after treatment: a systematic and narrative review. Cancers (Basel) 2021; 13 (08) 1846
10 Rogers L, Barani I, Chamberlain M. et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015; 122 (01) 4-23
11 Biczok A, Karschnia P, Vitalini R. et al. Past medical history of tumors other than meningioma is a negative prognostic factor for tumor recurrence in meningiomas WHO grade I. Acta Neurochir (Wien) 2021; 163 (10) 2853-2859
12 Spille DC, Adeli A, Sporns PB. et al. Predicting the risk of postoperative recurrence and high-grade histology in patients with intracranial meningiomas using routine preoperative MRI. Neurosurg Rev 2021; 44 (02) 1109-1117
13 Behling F, Hempel JM, Schittenhelm J. Brain invasion in meningioma-a prognostic potential worth exploring. Cancers (Basel) 2021; 13 (13) 3259
14 Chotai S, Schwartz TH. The Simpson grading: is it still valid?. Cancers (Basel) 2022; 14 (08) 2007
15 Liu N, Song SY, Jiang JB, Wang TJ, Yan CX. The prognostic role of Ki-67/MIB-1 in meningioma: a systematic review with meta-analysis. Medicine (Baltimore) 2020; 99 (09) e18644
16 Kwon SM, Kim JH, Kim YH. et al. Clinical implications of the Mitotic Index as a predictive factor for malignant transformation of atypical meningiomas. J Korean Neurosurg Soc 2022; 65 (02) 297-306
17 Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer 2022; 128 (01) 47-58
18 Mirian C, Duun-Henriksen AK, Juratli T. et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry 2020; 91 (04) 378-387
19 Li H, Huang H, Zhang X. et al. Postoperative long-term independence among the elderly with meningiomas: function evolution, determinant identification, and prediction model development. Front Oncol 2021; 11: 639259
20 Zhang GJ, Liu XY, You C. Clinical factors and outcomes of atypical meningioma: a population-based study. Front Oncol 2021; 11: 676683
21 Zhang J, Zhang G, Cao Y. et al. A magnetic resonance imaging-based radiomic model for the noninvasive preoperative differentiation between transitional and atypical meningiomas. Front Oncol 2022; 12: 811767
22 Li N, Mo Y, Huang C. et al. A clinical semantic and radiomics nomogram for predicting brain invasion in WHO grade II meningioma based on tumor and tumor-to-brain interface features. Front Oncol 2021; 11: 752158
23 Peng S, Cheng Z, Guo Z. Diagnostic nomogram model for predicting preoperative pathological grade of meningioma. Transl Cancer Res 2021; 10 (09) 4057-4064
24 Jia Z, Yan Y, Wang J. et al. Development and validation of prognostic nomogram in patients with WHO grade III meningioma: a retrospective cohort study based on SEER database. Front Oncol 2021; 11: 719974
25 Lin Y, Dai P, Lin Q, Chen J. A predictive nomogram for atypical meningioma based on preoperative magnetic resonance imaging and routine blood tests. World Neurosurg 2022; 163: e610-e616
26 Nassiri F, Mamatjan Y, Suppiah S. et al; International Consortium on Meningiomas. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-oncol 2019; 21 (07) 901-910
27 Stupp R, Mason WP, van den Bent MJ. et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
28 Stupp R, Hegi ME, Mason WP. et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10 (05) 459-466
29 Sharma A, Graber JJ. Overview of prognostic factors in adult gliomas. Ann Palliat Med 2021; 10 (01) 863-874
30 Chen K, Duan P, Jiang P. Prognostic value of preoperative seizure in adult glioblastoma: a systematic review and meta-analysis. Asian J Surg 2021; 44 (07) 994-995
31 Parsons DW, Jones S, Zhang X. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321 (5897) 1807-1812
32 Montemurro N, Perrini P, Rapone B. Clinical risk and overall survival in patients with diabetes mellitus, hyperglycemia and glioblastoma multiforme. a review of the current literature. Int J Environ Res Public Health 2020; 17 (22) 8501
33 Revilla-Pacheco F, Rodríguez-Salgado P, Barrera-Ramírez M. et al. Extent of resection and survival in patients with glioblastoma multiforme: systematic review and meta-analysis. Medicine (Baltimore) 2021; 100 (25) e26432
34 Bapuraj JR, Wang N, Srinivasan A, Rao A. Advanced imaging and computational techniques for the diagnostic and prognostic assessment of malignant gliomas. Cancer J 2021; 27 (05) 344-352
35 Corr F, Grimm D, Saß B. et al. Radiogenomic predictors of recurrence in glioblastoma-a systematic review. J Pers Med 2022; 12 (03) 402
36 Yu W, Zhang L, Wei Q, Shao A. O⁶-Methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol 2020; 9: 1547
37 McAleenan A, Kelly C, Spiga F. et al. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Database Syst Rev 2021; 3 (03) CD013316
38 Zhou Y, Yang L, Zhang X. et al. Identification of potential biomarkers in glioblastoma through bioinformatic analysis and evaluating their prognostic value. BioMed Res Int 2019; 2019: 6581576
39 Zhang LL, Zhang LF, Shi YB. miR-24 inhibited the killing effect of natural killer cells to colorectal cancer cells by downregulating Paxillin. Biomed Pharmacother 2018; 101: 257-263
40 Hyduk SJ, Oh J, Xiao H, Chen M, Cybulsky MI. Paxillin selectively associates with constitutive and chemoattractant-induced high-affinity alpha4beta1 integrins: implications for integrin signaling. Blood 2004; 104 (09) 2818-2824
41 Desiniotis A, Kyprianou N. Significance of talin in cancer progression and metastasis. Int Rev Cell Mol Biol 2011; 289: 117-147
42 McCarthy MM, Wright CL, Schwarz JM. New tricks by an old dogma: mechanisms of the Organizational/Activational Hypothesis of steroid-mediated sexual differentiation of brain and behavior. Horm Behav 2009; 55 (05) 655-665
43 Huang Z, Wang H, Sun D, Liu J. Identification of Paxillin as a prognostic factor for glioblastoma via integrated bioinformatics analysis. BioMed Res Int 2022; 2022: 7171126
44 Amer RG, Ezz El Arab LR, Abd El Ghany D, Saad AS, Bahie-Eldin N, Swellam M. Prognostic utility of lncRNAs (LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme (GBM). J Neurooncol 2022; 158 (03) 435-444
45 Barzegar Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. J Drug Target 2019; 27 (03) 257-269
46 Abdoli Shadbad M, Hosseinkhani N, Asadzadeh Z, Brunetti O, Silvestris N, Baradaran B. The prognostic value of CD133 in predicting the relapse and recurrence pattern of high-grade gliomas on MRI: a meta-analysis. Front Oncol 2021; 11: 722833
47 Gorlia T, van den Bent MJ, Hegi ME. et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008; 9 (01) 29-38
48 Gittleman H, Lim D, Kattan MW. et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-oncol 2017; 19 (05) 669-677
49 Gittleman H, Cioffi G, Chunduru P. et al. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neurooncol Adv 2019; 1 (01) vdz007
50 Jin Y, Wang Z, Xiang K. et al. Comprehensive development and validation of gene signature for predicting survival in patients with glioblastoma. Front Genet 2022; 13: 900911
51 Huang K, Rao C, Li Q. et al. Construction and validation of a glioblastoma prognostic model based on immune-related genes. Front Neurol 2022; 13: 902402
52 Wang S, Xu X. An immune-related gene pairs signature for predicting survival in glioblastoma. Front Oncol 2021; 11: 564960
53 Wang GM, Cioffi G, Patil N. et al. Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro-oncol 2022; 24 (02) 302-310
54 Gittleman H, Ostrom QT, Stetson LC. et al. Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. Neurooncol Pract 2019; 6 (06) 451-462
55 Ostrom QT, Rubin JB, Lathia JD, Berens ME, Barnholtz-Sloan JS. Females have the survival advantage in glioblastoma. Neuro-oncol 2018; 20 (04) 576-577
56 Patil N, Somasundaram E, Waite KA. et al. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. J Neurooncol 2021; 155 (03) 363-372
57 Tewarie IA, Senders JT, Kremer S. et al. Survival prediction of glioblastoma patients-are we there yet? A systematic review of prognostic modeling for glioblastoma and its clinical potential. Neurosurg Rev 2021; 44 (04) 2047-2057